Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Comments to CMS Concerning CLFS Gapfill Preliminary Determinations for GS Codes 81425, 81426, and 81427
-
ACMG Responds to FDA’s Approval for DTC Testing for Three BRCA Gene Mutations
-
Group Sign-on Letter to Congress Supporting the Medical Nutrition Equity Act (MNEA)
-
ACMG Comments to CMS on Proposed NCD for Coverage of NGS for Medicare Beneficiaries with Advanced Cancer (CAG-00450N)
-
Group Sign-on Letter to Congress Supporting the Local Coverage Determination Clarification Act of 2017
-
ACMG Board Statement Regarding 2018 ACMG Annual Meeting to Be Held in Charlotte, NC and Discriminatory Legislation
-
ACMG Efforts Lead AMA Resolution 122 to Support Coverage of Medical Food Products
-
ACMG Response to Expansion of Direct-to-Consumer Genetic Testing
-
ACMG Letter to Congress Supporting the Accurate Education for Prenatal Screenings Act (HR 3441)
-
Joint Comments to CMS Concerning MolDx Program, Medicare Coverage, and Impact on MoPath Gapfill Determinations